You just read:

Trek Therapeutics Initiates Phase 2a Study of Faldaprevir and TD-6450, With and Without Ribavirin, in Patients with HCV GT 1b.

News provided by

Trek Therapeutics

21 Jun, 2016, 09:30 ET